CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 328 enrolled
Drug / intervention
CyclASol topical ocular, eye drops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03292809
NCT03292809Phase 3Completed

A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)

Novaliq GmbH·interventional·Posted Sep 26, 2017·Updated Dec 22, 2022

In Brief

A Phase 3 clinical trial evaluating CyclASol topical ocular, eye drops and Vehicle topical ocular, eye drops for Dry Eye Disease. Completed, enrolled 328 participants across 9 sites.

Detailed Summary

The objective of this study is to assess the efficacy, safety, and tolerability of CyclASol Ophthalmic Solution in comparison to vehicle for the treatment of the signs and symptoms of DED.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedSep 26, 2017
Enrollment StartOct 19, 2017
Primary CompletionMay 22, 2018
Study CompletionJun 20, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.8 years ago

Interventions

CyclASol topical ocular, eye dropsdrug

Cyclosporine A solution in vehicle

Vehicle topical ocular, eye dropsdrug

Vehicle